GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know

What Happened?

A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.

Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales.

While the sector is traditionally defensive, the hot PPI print creates a two-pronged headwind. First, rising service-sector inflation (up 1.2% monthly) increases the operating costs for hospital systems and providers. Second, as inflation becomes a dominant political issue, drug companies' visible price-setting power makes them a primary target for regulatory intervention.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

Healthcare Technology for Patients company GoodRx (NASDAQ:GDRX) fell 2.6%. Is now the time to buy GoodRx? Access our full analysis report here, it’s free. Testing & Diagnostics Services company RadNet (NASDAQ:RDNT) fell 2.6%. Is now the time to buy RadNet? Access our full analysis report here, it’s free. Senior Health, Home Health & Hospice company Addus HomeCare (NASDAQ:ADUS) fell 3.2%. Is now the time to buy Addus HomeCare? Access our full analysis report here, it’s free. Therapeutics company Novavax (NASDAQ:NVAX) fell 2.8%. Is now the time to buy Novavax? Access our full analysis report here, it’s free. Research Tools & Consumables company Mettler-Toledo (NYSE:MTD) fell 2.6%. Is now the time to buy Mettler-Toledo? Access our full analysis report here, it’s free.

Zooming In On Addus HomeCare (ADUS)

Addus HomeCare’s shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The previous big move we wrote about was 8 days ago when the stock dropped 4.6% on the news that the company reported first-quarter financial results that showed a miss on revenue expectations, which overshadowed a beat on earnings per share (EPS).

Despite adjusted earnings of $1.62 per share surpassing analyst forecasts of $1.54, the company's revenue of $363.6 million fell short of Wall Street estimates. While this revenue figure represented a 7.7% increase from the prior year, sales volumes were flat year on year, pointing to a potential slowdown. The market's negative reaction reflects investor caution, as the revenue miss outweighed the positive earnings surprise and sent the stock lower.

Story Continues

Addus HomeCare is down 11.2% since the beginning of the year, and at $94.61 per share, it is trading 22.9% below its 52-week high of $122.75 from October 2025. Despite the year-to-date decline, investors who bought $1,000 worth of Addus HomeCare’s shares 5 years ago would now be looking at an investment worth $1,029.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

View Comments